Feature | May 01, 2012

CMS to Cover TAVR for Medicare Patients

Medicare patients will be covered for transcatheter aortic valve replacements

May 1, 2012 – The Centers for Medicare and Medicaid Services (CMS) announced today it will now cover transcatheter aortic valve replacement (TAVR) for Medicare patients under certain conditions. The coverage decision announced by CMS Acting Administrator Marilyn Tavenner offers important new technology to some of Medicare’s sickest patients.

Aortic valve replacements are used in patients whose aortic heart valves are damaged, causing the valve to narrow – a condition known as aortic stenosis. Once patients experience symptoms of aortic stenosis, treatment is critical to improve their chances of survival. Until recently, aortic stenosis has been treatable only through invasive surgery. In contrast, TAVR allows doctors to replace a patient’s aortic valve through a small percutaneous opening in the leg. This less invasive procedure gives patients who cannot undergo open-heart surgery a new way to repair their damaged heart valve.

“We are pleased with this decision and the increased access to treatment options it will provide,” said Tavenner. “This decision is particularly important as it highlights cooperative efforts among CMS, the U.S. Food and Drug Administration (FDA), the Agency for Healthcare Research and Quality, medical specialty societies and the medical device industry.”

This final national coverage decision is one of the first coverage decisions completed under a mutual memorandum of understanding between CMS and the FDA, a joint effort aimed at getting sometimes-lifesaving, new technology to patients sooner.

Because this technology is still relatively new, it is important that these procedures are performed by highly trained professionals in optimally equipped facilities. Therefore, this decision uses “coverage with evidence development,” which, as a condition of coverage, will require certain provider, facility and data collection criteria to be met. Such requirements are important to ensure beneficiaries receive the safest and most appropriate care.

The decision includes the Edwards Lifesciences' Sapien valve, which is the only FDA-cleared transcatheter aortic valve. Medtronic’s CoreValve is currently being reviewed in a U.S. pivotal trial that will be used to seek final FDA review.

Edwards commended CMS for issuing a flexible National Coverage Determination (NCD) that authorizes coverage for current and future indications approved by the FDA. Edwards also noted that, under the NCD, coverage would extend to qualified noninferiority or equivalence clinical studies. Additionally, important but small patient populations can be covered under a qualified study. The company continues to support the collection of TAVR outcomes data in a qualified national prospective registry.

"We endorse the NCD's emphasis on the use of multi-disciplinary heart teams in the treatment of TAVR patients," said Michael A. Mussallem, Edwards' chairman and CEO. "While we are still analyzing the policy and its lengthy supporting decision memorandum, we believe that this policy can provide appropriate and prompt access to treatment for these very sick patients."

The decision can be found at: www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=257&ver=4&NcaName=Transcatheter+Aortic+Valve+Replacement+(TAVR)&bc=ACAAAAAAAAAA&

Related Content

News | Cath Lab| October 09, 2015
October 9, 2015 — Cardinal Health is launching its expanded portfolio in the cardiova
Shimadzu, MIX package, Trinias Cardiovascular suites, U.S. availability

Image courtesy of Shimadzu Medical Systems

Technology | Cath Lab| October 08, 2015
Shimadzu Medical Systems USA announced the availability of the MIX package for the Trinias Cardiovascular suites. Based...
ORSIF, radiation exposure for interventionalists, greater on left side of head, Ehtisham Mahmud
Feature | Radiation Dose Management| October 06, 2015
The results of a research study indicate that interventional cardiologists receive “very high” radiation exposure...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
Overlay Init